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ABSTRACT
Background: It has been recognized that Hepatitis B virus infection is endemic in Nigeria. Despite this, routine 
screening in pregnancy and treatment are not widely practiced in the country.
Objective: To identify the prevalence and pattern of the disease among the obstetric population in Ekiti State. 
Materials and Methods: A review of the records of 505 consecutively booked and consenting pregnant women at the 
antenatal clinics of the Ekiti State University Teaching Hospital, Ado - Ekiti. The duration of the study was from April 
2011 to November 2011. All the patients were screened for Hepatitis B surface antigen (HBsAg). Using a 
questionnaire, information retrieved included their socio-demographic characteristics, possible risk factors (blood 
transfusion and surgery) and HBsAg screening result. 
Results: 20 of the 505 pregnant women were seropositive for HBsAg giving prevalence of 4.0%. Multiparous women 
aged between 30 - 34 years and with secondary education had the highest proportion of infected people although these 
associations did not reach significant levels. More women in the latter half of pregnancy were HBsAg seropositive (p 
< 0.05).
Conclusion: It is recommended that all pregnant women be routinely screened for HBV, and preventive measures 
emphasized to reduce the burden of HBV infection.
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INTRODUCTION
Hepatitis B virus (HBV) is a blood borne and 
sexually transmitted pathogen that could be 
acquired through intravenous drug use, sexual 
intercourse with infected partners, and perinatal 
transmission from mother to child among others. 
Hepatitis B is one of the most common infectious 
diseases reaching hyper-endemic proportions in 
sub-Saharan Africa and Asia. While it results in 
2million deaths annually, about 400million people 
are chronically infected with the virus with the 
attendant risks of liver cirrhosis and hepatocellular 
carcinoma which are responsible for 5 – 10% of 
, , , , 
cases of liver transplantation.  
In Nigeria, HBV spot surveys amongst pregnant 
women revealed rates ranging between 2.19% and 
, 15.1%.  Without intervention, the risk of peri-natal 
HBV transmission could be as high as 70 – 90% by 
the sixth month of life, especially in infants born to 
women who are Hepatitis B core antigen (HBeAg)-
positive, with about 90% of these children 
remaining chronically infected. Children born to 
HBsAg-positive mothers who do not become 
infected during the peri-natal period remain at a 
high risk of infection during early childhood. 
Vertical transmission of HBV can be minimized by 
vaccination of the newborn, but this can only be 
administered when the HBV status of the pregnant 
woman is known.
Although it does not appear that acute HBV 
infection increases mortality during pregnancy or 
that it has teratogenic effects, a higher incidence of 
low birth weight and prematurity has been 
10
reported.  Also, Tse et al described an association of 
maternal HBV infection (HBsAg positive) with 
gestational diabetes mellitus and antepartum 
haemorrhage. Some studies have shown that in a 
proportion of women, there are effects of pregnancy 
on hepatitis B including hepatitis flares with or 
without HBeAg seroconversion within the first 
months after delivery, exacerbation of chronic 
hepatitis and even fulminant hepatic failure in the 
peripartum period. 
Also, HBV can be transmitted to family members 
and healthcare providers who care for the infected 
postpartum women possibly by contact of non-
intact skin or mucous membrane with secretions or 
blood (e.g. lochia) containing HBV.
The benefits of detection of infected pregnant 
women include not only identification of infants 
who require prophylaxis, but of women who might 
need treatment, and sexual and household contacts 
who will benefit from testing, counselling, 
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vaccination or therapy if indicated.
This study is thus, aimed at generating information 
on the pattern of HBV infection amongst pregnant 
women in the apex health institution in Ekiti state 
and hopefully provide a basis for the monitoring of 
the trend and formulation of strategies aimed at 
controlling the spread of the disease.  
MATERIALS AND METHODS
Design: A retrospective review of the case records of 
consecutively booked and consenting pregnant 
patients obtained from the Medical Records 
Department.
Setting: The Antenatal Clinics of the Ekiti State 
University Teaching Hospital (EKSUTH), Ado – 
Ekiti, Ekiti State. EKSUTH is the apex health 
institution in the state, receiving both physician- and 
self-referrals from all the government hospitals in 
the state, private health facilities and neighbouring 
states. About 1000 new clients are registered for 
antenatal care annually.
Study Duration: April 2011 to November 2011.
Method: At the booking (antenatal) clinic, every 
woman was counselled and consent obtained for 
HBV screening along with other routine tests 
(Packed Cell Volume [PCV], Haemoglobin 
G e n o t y p e ,  B l o o d  G r o u p  a n d  H u m a n  
Immunodeficiency Virus status). 
Sample Collection and Preparation
Blood samples for HBV screening were collected 
aseptically by venepuncture using 5 ml sterile 
disposable hypodermic syringes and needles during 
the booking clinic, dispensed into labeled specimen 
bottles and transferred to the laboratory. Each 
clotted sample was centrifuged at 3,000 rpm for 
5mins to separate the serum. Only clear, non-
haemolyzed specimens were used. If the test could 
not take place immediately, the sera were extracted 
using micropipettes into plain tubes and stored at 2 - 
0
8 C until required, but not beyond 3 days after 
collection. 
The Principle of the Test Kit
Hepatitis B surface antigen (HBsAg) detection was 
done using the in vitro diagnostic kit manufactured 
by Grand Medical Diagnostic Limited, USA. The 
kit's test strip is a rapid chromatographic 
immunoassay for the qualitative detection of 
HBsAg in serum or plasma. The test strip contains a 
membrane (which is pre-coated with anti-HBsAg 
antibodies on the test line region of the strip) and 
anti-HBsAg-coated particles. During testing, the 
serum or plasma reacts with the particle to form a 
mixture. This mixture then migrates upward on the 
membrane chromatographically by capillary action 
to react with the antibodies on the membrane and 
generate a coloured line. The presence of the 
coloured line in the test region indicates a positive 
result, while its absence indicates a negative result. 
Detection of HBsAg
Specimens and test strips were allowed to equilibrate 
to room temperature prior to testing. The test strips 
were removed from their foil pouches and immersed 
into serum samples with arrows pointing towards the 
specimen for about 10 - 15secs. The strips were then 
placed on a non-absorbent flat surface for 15minutes, 
after which the results were read.  Positive samples 
generated two distinct red bands, one in the test 
region of the strips and another in the control region 
while negative samples had a colour band in the 
control region only. 
Data Retrieval
Using a pre-structured questionnaire, information 
about the socio-demographic characteristics of the 
patients, risk factors such as history of blood 
transfusion and surgical procedures and laboratory 
screening results were obtained.
Data Analysis: Data was encoded and analyzed 
using the SPSS version 16 statistical software 
package. Analysis included simple percentages and 
chi-square test where appropriate. A p value < 0.05 
was regarded as significant.
RESULTS
Out of 505 women screened during the study period, 
20 were seropositive for HBsAg giving a prevalence 
of 4.0%. From Table 1, women who were 
multiparous (para 2), aged 30 – 34 years with a 
secondary education and in the third trimester had 
the highest prevalence of the disease, though this 
finding did not reach statistically significant levels. 
Significantly more patients in the latter half of 
pregnancy were HBsAg positive (Table 2). There 
were more HBsAg-positive women who had been 
transfused in the past and with a previous history of 
surgeries than those without such histories. 
However, this observation was not significant (Table 
3).  
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CHARACTERISTICS FREQUENCY HBsAg POSITIVE %
AGE (years)
= 19 2 0 0
20 – 24 41 2 4.9
25 – 29 185 4 2.2
30 – 34 177 12 6.8

























































÷2 = 2.575, p = 0.631
GESTATIONAL AGE (weeks)
= 13 55 1 1.8
14 – 26 334 12 3.6
27 – 40 116 7 6.0
÷2 = 2.094, p = 0.351
Table 1: Patients' Characteristics versus HBsAg 
Seropositivity
Table 2: Pregnancy Stage versus HBsAg Seropositivity





NEGATIVE  POSITIVE  
1st Half (≤ 20 weeks) 236 5  241
2nd Half (21 – 40 weeks) 249 15  264
TOTAL 485 20  505
÷2 = 4.310, p = 0.038
 
Table 3: Risk Factors versus HBsAg Seropositivity 





















÷2 = 0.06, p = 0.807
DISCUSSION
Estimates have shown that about one-third of the 
population of the world has serological evidence of 
past or present infection by HBV and 350 million 
9, 
people are chronically infected.  The prevalence of 
HBV infection is especially high in South-East Asia 
and Sub-Saharan Africa, where more than 8% of the 
5population are HBsAg chronic carriers.  The 
prevalence of Hepatitis B surface antigenaemia from 
this study is 4.0%. This compares with other studies 
on perinatal HBV infection as follows: 





Onakewhor et ali 2008 Benin City, Edo State 2.19
Obi et alii 2006 Port Harcourt, Rivers 2.89
Akani et aliii 2005 Port Harcourt, Rivers 4.3
Agbede et aliv 2007 Ilorin, Kwara State 5.7










Mbaawuaga et alvi 2008
 
Markurdi, Borno State 11.0
Harry et alvii 1994
 
Maiduguri, Bauchi State 11.6
Ndams et al7 2008 Minna, Niger State  12.3
AFRICA
















Todd et alxi 2008 Afghanistan 1.53
Sahaf et alxii 2007 Iran 2.5
Kong et alxiii 1997 Hong Kong 10
Sharma et alxiv 1995 India 10
Lin et alxv 2003 Taiwan 12
Significant variations exist in the seroprevalence of 
HBV in pregnant women as can be deduced from the 
table above. Considerable variations have been 
noted even among various races and ethnic groups as 
is the case in the United States where the prevalence 
among the Asians is 6%, blacks 1%, whites 0.6% and 
11Hispanics 0.14%.  Also, cultural differences, 
diverse geographic variations, sexual behaviour and 
practices, and various study methodology may 
account for this wide disparity. 
Most of the women with the antigenaemia in this 
study were within the 30 – 34-year bracket. The age 
at which the individual becomes infected with HBV 
6
correlates with the route of infection.  In areas of 
high endemicity like sub-Saharan Africa, infections 
are generally acquired early in life, either at or 
shortly after birth, or early in childhood from 
exposure to members of the extended family who 
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may be carriers of HBV. Up to 95% of neonates and 
children under 5 years of age who are infected with 
HBV become chronic HBV carriers, although 
infection is generally subclinical because of their 
, 
immature immune systems.
Significantly more women in the latter half of 
pregnancy were positive for the HBsAg. Although 
this study did not distinguish active infections from 
carrier status, other authors have shown that acute 
HBV infection early in pregnancy is associated with 
a 10% perinatal transmission rate, and the rate 
increases substantially with HBV infection in the 
11third trimester.  Thus, the risk of transmission of 
HBV to neonates increases the later in gestation the 
acute infection occurs. This perinatal transmission 
or transmission during early childhood is 
responsible for the high rate of chronic infection in 
Asia and Africa. In fact, of the estimated 350 million 
individuals chronically infected with hepatitis B 
virus (HBV) worldwide, it is generally accepted that 
at least 50% acquired their infections either 
perinatally or in early childhood, especially in 
11
countries where HBV is endemic.  Therefore, 
preventing perinatal transmission is of high priority 
in the attempt to decrease the global burden of 
chronic HBV infection. Immunoprophylaxis with 
hepatitis B immune globulin (HBIG) and hepatitis B 
vaccine have been shown to be safe and effective 
strategies provided they are properly administered. 
Also, Lamivudine, an antiviral agent, has been 
employed during pregnancy. There are two 
principal indications for administration of antiviral 
agents to HBV-infected pregnant women: treatment 
of chronic hepatitis in the mothers and prevention of 
11perinatal HBV transmission to the newborns.
A limitation in this study was the use of HBsAg 
alone for screening as this approach does not 
discriminate between carrier state, viral replication 
or active infection. Assaying for other serological 
markers of HBV infection such as anti-HBs and 
anti-HBc antibodies (i.e. antibodies to the surface 
and core antigens respectively) [which are 
indicators of previous exposure to HBV infection], 
could have resulted into higher seroprevalence rate 
than reported in this study. Further studies are 
needed in this regard. Also, the benefits and cost 
implications of nationwide Hepatitis B vaccination 
and the safety and effectiveness of antiviral therapy 
in the reduction of the HBV burden need to be 
evaluated through large controlled trials.
CONCLUSION
The seroprevalence of antenatal Hepatitis B surface 
antigenaemia from this study falls within the 
previously quoted figures from studies within the 
nation, confirming what has been long recognized. 
Though the study did not discriminate between acute 
infections and chronic carrier status, more women 
were seropositive in the latter half of pregnancy 
which could imply an increased risk of perinatal 
transmission. Therefore, strategies to decrease this 
mode of acquisition should be considered to reduce 
the HBV burden. This would emphasize the need for 
an improvement in preventive measures because 
even with proper vaccination, 5 – 10% of infants of 
11
HBeAg-positive women become infected.
The possibility of managing HBV infection in 
pregnancy and in the newborn naturally increases the 
need for physician education about these strategies 
and their advantages. These include recognition of 
maternal HBV status through routine screening of all 
pregnant women, and minimizing the risk for 
perinatal transmission of infection via monitoring of 
antigen status, avoiding neonatal contact with lochia, 
antiviral therapy and immunoprophylaxis for the 
exposed newborns.
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